AstraZeneca Says High-level Results From BATURA Phase 3b Trial Showed Airsupra (Albuterol/Budesonide) Met The Primary Endpoint, Demonstrating A Statistically Significant And Clinically Meaningful Reduction In The Risk Of A Severe Exacerbation When...
AstraZeneca Says High-level Results From BATURA Phase 3b Trial Showed Airsupra (Albuterol/Budesonide) Met The Primary Endpoint, Demonstrating A Statistically Significant And Clinically Meaningful Reduction In The Risk Of A Severe Exacerbation When...
阿斯利康表示，BATURA 第30億期試驗的高水平結果顯示，Airsupra（沙丁胺醇/布地奈德）滿足了主要終點，顯示出在...時嚴重加重風險的統計顯著和臨床意義顯著降低。
AstraZeneca Says High-level Results From BATURA Phase 3b Trial Showed Airsupra (Albuterol/Budesonide) Met The Primary Endpoint, Demonstrating A Statistically Significant And Clinically Meaningful Reduction In The Risk Of A Severe Exacerbation When Used As An As-needed Rescue Medication In Response To Symptoms Compared To As-needed Albuterol
阿斯利康表示，BATURA第30億階段試驗的高水平結果顯示，Airsupra（沙丁胺醇/布地奈德）達到了主要終點，證明與即用型沙丁胺醇相比，當作爲需要時的救助藥物以響應症狀使用時，顯著減少了嚴重惡化風險，達到了統計學上顯著和臨床上有意義的效果
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。